JYNT · Intrinsic value
Is The Joint Corp. (JYNT) overvalued or undervalued?
TickerWorth's fair value for The Joint Corp. (JYNT) is $10.06 a share, against the delayed market price of $7.18 (priced within our range of $6.37 – $11.64). no growth rate up to 300%/yr justifies the price under these economics We do not call it over- or undervalued from inside our range.
Model by Miraaj Patel · generated from market data · Updated Oct 19, 2026 · How these pages are made
Is JYNT fairly valued?
- Fair value
- $10.06
- Market price
- $7.18
- Upside to fair value
- +40.2%
- Verdict
- Priced within our range of $6.37 – $11.64
Reverse DCF, on our cash-flow model rather than the fair value above: no growth rate up to 300%/yr justifies the price under these economics
What is JYNT's TickerWorth Score?
Scores higher than most companies we compare it with
Compared with Healthcare companies in US
Its strongest point: growing quickly. Its weakest: recent price trend has been weak.
- Value · 46 of 100
Cheaper than 46% of Healthcare companies in US
- Price vs worth · 82 of 100
- Quality · 56 of 100
More profitable than 56% of Healthcare companies in US
- Financial health · 80 of 100
Financially stronger than 80% of Healthcare companies in US
- Growth · 89 of 100
Growing faster than 89% of Healthcare companies in US
- Momentum · 10 of 100
Outperformed 10% of Healthcare companies in US over the past year
Confidence: Medium confidence · Scored
Get the Undervalued Company of the Week.
JYNT DCF valuation, input by input
TickerWorth's fair value for The Joint Corp. (JYNT) is $10.06 a share, against the delayed market price of $7.18 (priced within our range of $6.37 – $11.64). We do not call it over- or undervalued from inside our range. It is a model estimate, and every input behind it is sourced below.
Read the full reasoning
For this company that blend leans on peer multiples: our discounted-cash-flow model understates a business growing this fast, so read the gap as how the market prices it against comparable companies, not as a finding on cash flow. This is an educational model, not a price target or a recommendation.
The valuation discounts The Joint Corp.'s projected free cash flows at a weighted-average cost of capital (WACC) of 10.2%, with a long-run terminal growth rate of 2.5%. About 51% of the enterprise value comes from the terminal value — the portion beyond the explicit forecast window — which is typical for a stable, cash-generative business and a reminder that small changes in the discount rate or terminal growth assumption swing the intrinsic value meaningfully.
Sensitivity matters more than any single number. Across a reasonable band of discount-rate assumptions, JYNT's modeled DCF value ranges from about $0.97 to $1.14 per share. If that range still sits below today's price, the market is optimistic relative to the model across the whole band; if it brackets the price, the stock is roughly fairly valued on our assumptions. Use the interactive slider to see exactly where your own cost-of-capital view lands.
How to read this page: the DCF fair value is what The Joint Corp. would be worth if its cash flows grow as modeled and are discounted at the stated WACC. The assumptions table shows every input and its source; the reverse-DCF shows what the market believes; the sensitivity band shows how fragile the answer is. None of this is investment advice — it is a transparent, auditable framework for forming your own view of JYNT's intrinsic value. Figures update as new filings and prices come in.
Every input behind JYNT's DCF
| Input | Value |
|---|---|
| Base-year revenueLive feed — totalRevenue (TTM) | $58,550,000 |
| Base EBIT marginComputed — trailing operatingMargins, held roughly flat | 3.2% |
| Forecast revenue growthESTIMATEAssumption — TickerWorth's 5-year explicit forecast | 10% → 9% → 7% → 6% → 4% |
| Risk-free rateLive feed — US 10-year Treasury yield (^TNX) | 5.3% |
| BetaLive feed — yfinance, 5-year monthly beta vs the S&P 500 (clamped to 0.4–2.5) | 1.06 |
| Terminal growthESTIMATEAssumption — TickerWorth house default 2.5%, held below WACC | 2.5% |
| Diluted sharesLive feed — sharesOutstanding | 14M |
| Market priceLast known price · as of 2026-10-19 21:02 UTC | $7.17 |
Change JYNT's assumptions
The discount-rate dial and the editable model
ProChange growth, margin and WACC yourself — Pro (7-day free trial, card required).
What does The Joint Corp. do?
What does it do?
The Joint Corp. operates and is a franchisor and operator of chiropractic clinics in the United States. It operates in the Medical Care Facilities industry (Healthcare sector), headquartered in United States. The company employs roughly 202 people.
How does it make money?
The business turns $55M in annual revenue into profit. Out of every $100 of sales, about $3 is left as operating profit (operating margin of 3.2%), after a 82% gross margin on the products/services it sells. After all costs, taxes and interest, 6.5% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks solid: carries modest debt (0.1× equity), comfortably covers its short-term bills (1.8× current ratio), and is currently profitable.
Who at JYNT filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| Bowman Scott Justin | Chief Financial Officer | Shares withheld (tax) | $11,734.56 | Form 4 for Bowman Scott Justin (opens sec.gov in a new tab) | |
| Pant Milind | Director | Grant / award | — | Form 4 for Pant Milind (opens sec.gov in a new tab) | |
| Karrmann Sandra R | Director | Grant / award | — | Form 4 for Karrmann Sandra R (opens sec.gov in a new tab) | |
| Grandpre Christopher M | Director | Grant / award | — | Form 4 for Grandpre Christopher M (opens sec.gov in a new tab) | |
| DaVella Ronald V | Director | Grant / award | — | Form 4 for DaVella Ronald V (opens sec.gov in a new tab) | |
| Rubel Matthew E | Director | Grant / award | — | Form 4 for Rubel Matthew E (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Common questions
What is JYNT's intrinsic value?
TickerWorth's blended fair value for The Joint Corp. (JYNT) is $10.06 per share, versus a market price of $7.18 (priced within our range of $6.37 – $11.64).
Is JYNT overvalued or undervalued?
Priced within our range of $6.37 – $11.64 at $7.18. We don't call JYNT overvalued or undervalued from a range. This is an educational estimate, not advice.
What discount rate is used for JYNT?
A WACC of 10.2% and a terminal growth rate of 2.5%.
Is The Joint stock undervalued?
TickerWorth's fair value for The Joint Corp. (JYNT) is $10.06 against a market price of $7.18. Our read: Priced within our range of $6.37 – $11.64. This is a model estimate, not investment advice.
The Joint (JYNT) DCF valuation and fair value
Our fair value for The Joint Corp. (JYNT) is $10.06, built on a 10.2% discount rate (WACC) and 2.5% terminal growth. It blends our discounted-cash-flow model with other valuation lenses. Every assumption is listed on this page with its source.
What growth is priced into The Joint stock?
no growth rate up to 300%/yr justifies the price under these economics This is a reverse DCF: it holds our cash-flow model's other inputs and solves for the revenue growth that makes the model equal today's price of $7.18. A model estimate, not investment advice.
The Joint (JYNT) insider trading
The most recent insider filing (SEC Form 4) for The Joint Corp. (JYNT): Bowman Scott Justin, Chief Financial Officer, shares withheld (tax) on 2026-06-10. The latest filings are listed on this page. A disclosure, not a signal to trade.
Not investment advice. TickerWorth Score is a model output.
Educational tool. Every output reflects the assumptions shown — not a prediction and not investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public filings and market data that can be wrong.